1[1]Chamberlain RS. Prospects for the therapeutic use of anticancer vaccines[J]. Drugs, 1999,57 (3): 309 - 325.
2[2]Schlag P, Manasterski M, Gemeth Thomas , et al. Active specific immuno-therapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evalution of clinical response of a phase Ⅱ trial[J]. Cancer Immunol Immunother , 1992,35(5): 325 - 330.
3[3]Guo YJ, Wu MC, Chen H, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells[J].Sci ,1994, 263: 518-520.
4[4]Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients[J]. Proc Natl Acad Sci USA, 1987, 84(9): 2911-2915.
5[5]Salgaller ML, Marincola FM, Cormier JN, et al. Immunization against epitopes in the human melanoma antigen gp100 following patients immunization with synthetic peptides[J]. Cancer Res, 1996,56(20) :4749- 4757.
6[6]Saleh MN, Stapleton JD, Khazaeli MB, et al. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen[J ]. J Immunol , 1993,151 (6): 3390 - 3398.
7[7]Mittelman A, Chen ZJ,Yang H,et al . Human high molecular weight melanoma-associated antigen (HMW-MAA)mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage Ⅳ melanoma[J]. Proc Natl Acad Sci U S A ,1992, 89(2): 466-470.
8[8]Irvine KR, Rao JB, Rosenberg SA, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases[J ]. J Immunol,1996,156 (1) :238 - 245.
9[9]Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class Ⅰ major histocompatibility complex gene with DNA-liposome complexes[J]. Proc Natl SCi U S A , 1996, 93(26): 15388- 93.
10[10]Conry RM, Lobuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector[J ].Caner Res , 1995,55(7): 1397 - 1400.
